PharmaFocus Today – Page 2 – media

Received Notice of Approval for Drug Clinical Trial

Hengrui Pharma announced on January 20, 2026, that the company and its subsidiaries, Suzhou Shengdia Biopharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd., have received the “Notice of Approval for Drug Clinical Trial” issued by the National Medical Products Administration (NMPA) for SHR-9839 for Injection (sc) and HRS-4642 Injection. Clinical trials for these drugs will commence in the near future. Additionally, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the “Notice of Approval for Drug Clinical Trial” from the NMPA for HRS-2141 Tablets (I) and (II), and will also begin clinical trials shortly. https://finance.eastmoney.com/a/202601203624765352.html
- Source: drugdu
- 39
- January 21, 2026
Breaking news! AstraZeneca to be delisted from Nasdaq.

On January 20 , Reuters reported that AstraZeneca announced a major restructuring of its listing : the company will delist its American Depositary Receipts ( ADS ) and debt securities from Nasdaq and directly list its common stock and debt products on the New York Stock Exchange. The changes will take effect after the close of trading on January 30 , 2026 . It is understood that AstraZeneca ‘s common stock and debt securities are expected to begin trading on the NYSE on February 2 , and will continue to use the stock code “AZN” to ensure trading continuity for investors. This restructuring of the listing structure is a core component of the unified listing plan approved by AstraZeneca shareholders. Following the implementation of the unified structure, AstraZeneca will shift from trading ADSs (representing its common stock at a 2-to-1 ratio) to directly listing its $0.25 common stock, thereby simplifying ...
- Source: drugdu
- 33
- January 21, 2026
XinYue Bio Secures Tens of Millions in Series A+ Follow-on Funding to Advance DEL+AI-Powered Drug Discovery

Xinyue Bio closes multi-million RMB Series A+ round with follow-on from XtalPi (2228.HK). This latest funding, secured within six months of XtalPi’s initial investment, underscores strong investor confidence. The funds will drive the R&D of Xinyue Bio’s “DEL+AI” platform and accelerate the clinical development of its pipeline, aiming to boost efficiency and success rates in early drug discovery. Synergy in Action: Building a New Engine for Drug R&D Xinyue Bio specializes in the advanced development and application of DNA-Encoded Library (DEL) technology, dedicated to empowering and advancing innovative drug discovery. The company’s proprietary DEL live-cell screening platform enables effective screening of membrane proteins that are difficult to express and purify. This not only expands the range of druggable targets accessible to DEL technology but also represents a screening approach that more closely mimics physiological conditions. As a pioneer in AI-driven drug discovery, XtalPi leverages a high-precision drug design platform that ...
- Source: drugdu
- 32
- January 21, 2026
20-Valent Pneumococcal Vaccine Approved for Clinical Trials

On January 19, AIM Vaccine (06660.HK) issued an announcement stating that its self-developed 20-valent pneumococcal polysaccharide conjugate vaccine (PCV20) has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA), officially granting approval for clinical trials. The vaccine is an optimized upgrade of the 13-valent pneumococcal conjugate vaccine (PCV13), adding 7 new serotypes for a total of 20 major prevalent serotypes. It is designed to prevent invasive diseases caused by these serotypes, such as pneumonia, meningitis, and bacteremia. https://finance.eastmoney.com/a/202601193623487020.html
- Source: drugdu
- 42
- January 20, 2026
ADC205 Tablets Received Approval for Drug Clinical Trial

Jiangsu Aidea Pharma Announcement: The company has received the “Drug Clinical Trial Approval Notice” approved and issued by the National Medical Products Administration (NMPA) on January 18, 2026. The notice approves clinical trials for the company’s investigational Class 2.3 modified new drug, Dolutegravir/Lamivudine/Tenofovir Tablets (ADC205), which is dedicated to the field of anti-HIV/AIDS. https://finance.eastmoney.com/a/202601193623367035.html
- Source: drugdu
- 41
- January 20, 2026
Sifang Optoelectronics makes strategic investment in Changhe Biotechnology

On January 16th, A strategic investment signing ceremony was held in Shanghai between Sifang Optoelectronics and Suzhou Changhe Biotechnology Co., Ltd. (hereinafter referred to as “Changhe Biotechnology”) . Sifang Optoelectronics acquired 57.14% of Changhe Biotechnology’s equity through a combination of capital transfer and capital increase using its own funds. This strategic integration with Changhe Biotechnology will allow the two companies to deeply integrate in areas such as product technology development, operational production, and sales channels, thereby leveraging Sifang Optoelectronics ‘ sensor technology…The company is expanding into more advanced biosafety testing instruments. Meanwhile, leveraging its expertise in core components within the sensor field, Sifang Optoelectronics will develop low-cost biosafety sensors for mass-market applications in home appliances, automobiles, and buildings. https://finance.eastmoney.com/a/202601193622798315.html
- Source: drugdu
- 35
- January 20, 2026
Mingde Bio plans to acquire a 51% stake in Hunan Lanyi through capital increase and acquisition

On the evening of January 19th that Mingde Biotechnology…(002932) issued an announcement stating that the company plans to acquire Lanyi (Hunan) Medical Devices in the first phase of the acquisition through capital increase and equity acquisition.The company acquired 51% equity in Hunan Lanyi Limited Company (hereinafter referred to as “Hunan Lanyi”). After the initial acquisition, Hunan Lanyi became a controlling subsidiary of the company and was included in the company’s consolidated financial statements. Through negotiation among the parties involved, the total transaction price for this capital increase and equity acquisition of 51% equity in Hunan Lanyi was RMB 35.701 million. Meanwhile, if Hunan Lanyi’s relevant operating conditions from 2026 to 2028 meet the relevant preconditions stipulated in the Acquisition Agreement, the Company will further acquire the remaining equity of Hunan Lanyi in accordance with the agreement. After the completion of the aforementioned two-stage acquisition, the Company will hold a total ...
- Source: drugdu
- 40
- January 20, 2026
accelerating the transition of CLL treatment into a “chemotherapy-free era”.

On January 1, 2026, the new version of the National Reimbursement Drug List officially came into effect. Orelabrutinib (Yinokai®), a novel BTK inhibitor independently developed by Innovent Biologics, has rapidly achieved medical insurance coverage for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, commonly known as “CLL”), benefiting more patients. On January 17, during the working meeting of the Chinese Society of Clinical Oncology (CSCO) Expert Committee on Leukemia, Lymphoma and Myeloma and the 2026 CSCO Hematologic Oncology Academic Conference held in Haikou, the “Press Conference on the Implementation of Orelabrutinib 1L CLL/SLL Indication Under Medical Insurance Coverage” was successfully held. Several leading experts in the field of lymphoma gathered at the event, including Professor Ma Jun from the Harbin Institute of Hematology and Oncology, Professor Li Jianyong from Jiangsu Provincial People’s Hospital, Professor Qiu Lugui from the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy ...
- Source: drugdu
- 37
- January 20, 2026
Clinical trials successful, development terminated.

Lyra Therapeutics recently decided to terminate all further development of its only candidate drug for the treatment of chronic sinusitis, LYR-210 , and lay off 28 employees, retaining only the CEO and CFO as caretaker managers to find a “strategic alternative.” Just six months ago, this absorbable intranasal implant achieved positive results in a Phase 3 trial, but now it has been shelved by the company itself. LYR-210 is manufactured using Lyra’s proprietary XTreo platform : microcrystalline mometasone furoate is uniformly dispersed within a polylactic-co-glycolic acid copolymer backbone to form a 2-cm-long flexible filament. After simple implantation into the middle nasal meatus by a physician, it continuously releases glucocorticoids for up to 24 weeks, directly acting on the inflamed mucosa. Its target population is patients with chronic sinusitis (CRS) without nasal polyps. In June 2025, the pivotal Phase 3 ENLIGHTEN 2 study of LYR-210 was completed. The trial was a ...
- Source: drugdu
- 38
- January 20, 2026
Takeda Pharmaceutical lays off employees in the US; AstraZeneca acquires remaining Chinese interests in GPC3 CAR-T therapy

Takeda Pharmaceuticals makes major adjustments to its US market strategy. According to recent media reports, Takeda is laying off 243 employees in the United States to cope with the market challenge of Trintellix losing its exclusive sales rights. However, Takeda also plans to hire more than 400 new positions to support the US launch and marketing of several potential new drugs. AstraZeneca continues to deepen its presence in the Chinese market. On January 16, CBMG announced an agreement with AstraZeneca, under which the latter will acquire CBMG’s 50% stake in the development and commercialization rights of C-CAR031 in China. This will grant AstraZeneca exclusive rights to develop, manufacture, and commercialize C-CAR031 globally. Under the terms of the agreement, CBMG will be entitled to receive up to $630 million from AstraZeneca, including upfront payments for the GPC3 project in China, as well as development, regulatory, and sales milestone payments. What other ...
- Source: drugdu
- 36
- January 20, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.